We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Backs Pfizer’s Bosulif After Cancer Fund Restructuring
NICE Backs Pfizer’s Bosulif After Cancer Fund Restructuring
The UK’s price watchdog is backing coverage for Pfizer’s Bosulif at a new discounted price, broadening access to the drug that was previously only available through the now-revamped Cancer Drugs Fund.